13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Titel:
13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Auteur:
Cho, B.C. Ahn, M-J. Baik, C. GarcĂa, R. Goldman, J.W. Kim, S-W. Lee, J.S. Nishio, M. Ponce, S. Salgia, R. Teraoka, S. Yoshida, T. Yu, H.A. Ambrose, H. Cosaert, J. Hartmaier, R. Maidment, J. Pluta, M. Okamoto, I.